Skip to main content

Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis

Buy Article:

$51.00 plus tax (Refund Policy)



Background: Central vein catheters, which are used in the treatment of cancer patients, are prone to thrombotic complications of the catheter or adjacent vein. Previous studies suggest that 1 mg warfarin daily (minidose) can significantly reduce that risk.

Aims: This study aims to establish whether minidose warfarin could reduce catheter-related thrombosis in adult patients with haematological malignancies.

Methods: Patients were randomly selected to receive warfarin or not. The end-points studied were: (i) occlusion by thrombus, (ii) removal of catheter for other reasons or (iii) 90 days free of thrombus.

Results: There was no significant difference in the incidence of catheter thrombosis or venous thrombosis and no significant variation in catheter survival between the study and control groups.

Conclusions: This study found no benefit of the routine use of minidose warfarin for prophylaxis of central vein catheter thrombosis in patients with haematolog- ical malignancies and therefore does not support the routine use of minidose warfarin for prophylaxis in such patients. (Intern Med J 2002; 32: 84–88)

Keywords: central venous catheters; thrombosis; warfarin

Document Type: Research Article


Affiliations: 1: Department of Haematology, Christchurch Hospital, and 2: Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand

Publication date: 2002-03-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more